Shukra Pharmaceuticals (NSE:SHUKRAPHAR) Cash Flow for Dividends: ₹0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHUKRAPHAR Shukra Pharmaceuticals Ltd NSE:SHUKRAPHAR
61 GF Score
Price ₹41.55
GF Value ₹8.56
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Shukra Pharmaceuticals Cash Flow for Dividends?

Shukra Pharmaceuticals NSE:SHUKRAPHAR +0.27% 61 Cash Flow for Dividends is ₹0.0 Mil as of Jun. 2026. GuruFocus rates NSE:SHUKRAPHAR with a GF Score™ of 61/100 and a GF Value™ of ₹8.56 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Shukra Pharmaceuticals's cash flow for dividends for the three months ended in Jun. 2026 was ₹0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Shukra Pharmaceuticals's annual payment of dividends increased from Mar. 2024 (₹-0.7 Mil) to Mar. 2025 (₹-43.8 Mil) but then declined from Mar. 2025 (₹-43.8 Mil) to Mar. 2026 (₹-4.4 Mil).

Shukra Pharmaceuticals Cash Flow for Dividends Related Terms

Shukra Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Shukra Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shukra Pharmaceuticals Cash Flow for Dividends Chart

Shukra Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.73 -0.70 -43.79 -4.38

Shukra Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SHUKRAPHAR
61GF Score
Shukra Pharmaceuticals Ltd NSE:SHUKRAPHAR
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shukra Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of ₹0.0 Mil mean?
Shukra Pharmaceuticals (NSE:SHUKRAPHAR) has a Cash Flow for Dividends of ₹0.0 Mil as of Jun. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Shukra Pharmaceuticals and its competitors.
Is Shukra Pharmaceuticals' Cash Flow for Dividends too high?
Shukra Pharmaceuticals' current Cash Flow for Dividends is ₹0.0 Mil. Overall, Shukra Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Cash Flow for Dividends compare to ?
Shukra Pharmaceuticals' Cash Flow for Dividends of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Shukra Pharmaceuticals and its competitors. Shukra Pharmaceuticals's current Cash Flow for Dividends is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (NSE:SHUKRAPHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.56, compared to a current price of ₹41.55 — trading 385.4% above its estimated fair value. The current Cash Flow for Dividends is ₹0.0 Mil. Shukra Pharmaceuticals' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Shukra Pharmaceuticals (NSE:SHUKRAPHAR), the current Cash Flow for Dividends is ₹0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shukra Pharmaceuticals (NSE:SHUKRAPHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued. The current stock price of ₹41.55 is trading 385.4% above its estimated GF Value™ of ₹8.56. GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:SHUKRAPHAR:

  • Cash Flow for Dividends: ₹0.0 Mil
  • GF Value™: ₹8.56 vs. price of ₹41.55 (385.4% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NSE:SHUKRAPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shukra Pharmaceuticals Business Description

Comparable Companies
Other Exchanges 524632:India
Address Judges Bunglow Road, Bodakdev, 3rd Floor, Dev House, Opposite WIAA Office, Ahmedabad, GJ, IND, 380054
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
61GF Score

Get the complete analysis for NSE:SHUKRAPHAR

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹41.55
Price
₹8.56
GF Value